CN1713902A - 包含罗氟司特和(r,r)－福莫特罗的协同组合物 - Google Patents

包含罗氟司特和(r,r)－福莫特罗的协同组合物 Download PDF

Info

Publication number
CN1713902A
CN1713902A CNA2003801036335A CN200380103633A CN1713902A CN 1713902 A CN1713902 A CN 1713902A CN A2003801036335 A CNA2003801036335 A CN A2003801036335A CN 200380103633 A CN200380103633 A CN 200380103633A CN 1713902 A CN1713902 A CN 1713902A
Authority
CN
China
Prior art keywords
roflumilast
formoterol
administration
daily dose
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2003801036335A
Other languages
English (en)
Chinese (zh)
Inventor
R·博伊姆
D·邦德舒
D·马克斯
C·维马
S·-L·沃林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Altana Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma AG filed Critical Altana Pharma AG
Publication of CN1713902A publication Critical patent/CN1713902A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2003801036335A 2002-11-27 2003-11-26 包含罗氟司特和(r,r)－福莫特罗的协同组合物 Pending CN1713902A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02026504.7 2002-11-27
EP02026504 2002-11-27

Publications (1)

Publication Number Publication Date
CN1713902A true CN1713902A (zh) 2005-12-28

Family

ID=32338001

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2003801036335A Pending CN1713902A (zh) 2002-11-27 2003-11-26 包含罗氟司特和(r,r)－福莫特罗的协同组合物

Country Status (31)

Country Link
US (1) US20060199865A1 (OSRAM)
EP (1) EP1567140B1 (OSRAM)
JP (1) JP2006508993A (OSRAM)
KR (1) KR20050094810A (OSRAM)
CN (1) CN1713902A (OSRAM)
AT (1) ATE399544T1 (OSRAM)
AU (1) AU2003288169B8 (OSRAM)
BR (1) BR0316475A (OSRAM)
CA (1) CA2506956C (OSRAM)
CO (1) CO5690571A2 (OSRAM)
CY (1) CY1110368T1 (OSRAM)
DE (1) DE60321954D1 (OSRAM)
DK (1) DK1567140T3 (OSRAM)
EA (1) EA009990B1 (OSRAM)
ES (1) ES2309374T3 (OSRAM)
HR (1) HRP20050580B1 (OSRAM)
IL (1) IL168307A (OSRAM)
IS (1) IS2576B (OSRAM)
MA (1) MA27538A1 (OSRAM)
ME (1) ME00488B (OSRAM)
MX (1) MXPA05005438A (OSRAM)
NO (1) NO334148B1 (OSRAM)
NZ (1) NZ540658A (OSRAM)
PL (1) PL214869B1 (OSRAM)
PT (1) PT1567140E (OSRAM)
RS (1) RS51082B (OSRAM)
SI (1) SI1567140T1 (OSRAM)
TN (1) TNSN05130A1 (OSRAM)
UA (1) UA83017C2 (OSRAM)
WO (1) WO2004047828A1 (OSRAM)
ZA (1) ZA200503307B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103784443A (zh) * 2014-02-18 2014-05-14 青岛市城阳区人民医院 一种包含沙美特罗和罗氟司特的药物组合产品

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
DE602004023921D1 (de) 2003-03-10 2009-12-17 Nycomed Gmbh Neues verfahren zur herstellung vonroflumilast
US8663694B2 (en) 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
WO2013077830A1 (en) * 2011-11-25 2013-05-30 Mahmut Bilgic Synergistilly active combinations of roflumilast and carmoterol

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
AU722859B2 (en) * 1996-11-11 2000-08-10 Sepracor, Inc. Process for the preparation of optically pure isomers of formoterol
AU734122B2 (en) * 1997-02-17 2001-06-07 Takeda Gmbh Compositions for the treatment of ARDS or IRDS containing 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4- (difluoromethoxy)benzamide and lung surfactant
SI0975347T1 (sl) * 1997-02-28 2008-08-31 Nycomed Gmbh Sinergistična kombinacija PDE inhibitorjev in agonistov adenilat ciklaze oziroma agonistov gvanil ciklize
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
HUP0103160A3 (en) * 1998-08-26 2002-11-28 Smithkline Beecham Corp Pharmaceutical compositions for treating pulmonary diseases containing pde4 inhibitor
US6303145B2 (en) * 1999-05-10 2001-10-16 Sepracor Inc. (S,R) formoterol methods and compositions
HU229439B1 (hu) * 1999-08-21 2013-12-30 Takeda Gmbh Roflumilast és salmeterol szinergetikus kombinációja
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
WO2002076933A1 (en) * 2001-03-22 2002-10-03 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
US7291608B2 (en) * 2001-04-30 2007-11-06 Glaxo Group Limited Anti-inflammatory 17.β.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.α

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103784443A (zh) * 2014-02-18 2014-05-14 青岛市城阳区人民医院 一种包含沙美特罗和罗氟司特的药物组合产品

Also Published As

Publication number Publication date
CY1110368T1 (el) 2015-04-29
WO2004047828A1 (en) 2004-06-10
MA27538A1 (fr) 2005-09-01
EP1567140B1 (en) 2008-07-02
TNSN05130A1 (en) 2007-05-14
ME00488B (me) 2011-10-10
PL375632A1 (en) 2005-12-12
CA2506956A1 (en) 2004-06-10
HRP20050580B1 (hr) 2014-04-11
CA2506956C (en) 2012-10-02
DK1567140T3 (da) 2008-11-03
BR0316475A (pt) 2005-10-11
AU2003288169A1 (en) 2004-06-18
NO334148B1 (no) 2013-12-16
UA83017C2 (uk) 2008-06-10
CO5690571A2 (es) 2006-10-31
ZA200503307B (en) 2006-11-29
KR20050094810A (ko) 2005-09-28
NO20053023L (no) 2005-06-20
SI1567140T1 (sl) 2008-12-31
NZ540658A (en) 2007-03-30
EA200500865A1 (ru) 2005-12-29
AU2003288169B2 (en) 2010-01-07
DE60321954D1 (de) 2008-08-14
IS7899A (is) 2005-06-20
RS20050383A (sr) 2007-08-03
EP1567140A1 (en) 2005-08-31
MXPA05005438A (es) 2005-08-03
US20060199865A1 (en) 2006-09-07
ES2309374T3 (es) 2008-12-16
IL168307A (en) 2010-12-30
HRP20050580A2 (en) 2006-08-31
PL214869B1 (pl) 2013-09-30
AU2003288169B8 (en) 2010-08-26
HK1081862A1 (en) 2006-05-26
JP2006508993A (ja) 2006-03-16
IS2576B (is) 2010-02-15
ATE399544T1 (de) 2008-07-15
EA009990B1 (ru) 2008-04-28
RS51082B (sr) 2010-10-31
PT1567140E (pt) 2008-09-24

Similar Documents

Publication Publication Date Title
CN1314811A (zh) 治疗肺病的方法
CN1235545A (zh) 含有氯雷他定和减充血剂的用于治疗哮喘的组合物
CN100346777C (zh) 包括罗氟斯特和福莫特罗的新的协同组合
CN1713902A (zh) 包含罗氟司特和(r,r)－福莫特罗的协同组合物
US20120101076A1 (en) Carbonate derivatives for the treatment of cough
HK1081862B (en) Synergistic combination comprising roflumilast and (r,r)-formoterol
HK1081861B (en) New synergistic combination comprising roflumilast and formoterol

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication